Trial Profile
A randomized, double-blind, placebo-controlled phase 3 study evaluating the efficacy and safety of vibegron in Japanese patients with overactive bladder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Jan 2020
Price :
$35
*
At a glance
- Drugs Vibegron (Primary)
- Indications Overactive bladder; Urinary incontinence
- Focus Therapeutic Use
- 28 Jan 2020 Results (n=989) of post hoc analysis of randomized, placebo-controlled, double-blind comparative phase 3 study, assessing Efficacy of vibegron on severe urgency urinary incontinence related to overactive bladder, published in the BJU International
- 11 Jul 2018 New trial record